Home » Newsletters » BioWorld Science

BioWorld Science

May 18, 2000

View Archived Issues

DNA-based vaccine provokes powerful immune response in tumor-bearing mice

Important labeling changes reported for Agenerase

Structure of COX-2 reaction revealed; COX-2-selective compound developed

Researchers find protein not only attracts but also repels immune cells

New calcium antagonists designed by Chinese university researchers

Researchers create synthetic vessels to carry biomaterials for gene therapy and other applications

FDA-approved slower Topamax titration schedule improves tolerability

Company Profile: AdipoGenix

Texas Biotechnology reports progress during Q1 2000

FDA requests additional animal data for Vasomax

Antifungal cystothiazole compounds discovered by Ajinomoto

Schering-Plough presents new humanized anti-IL-5 MAbs for asthma

Use of RAR antagonists or inverse agonists as male contraceptives described by Allergan

New tryptase inhibitors from Bayer useful for allergic disorders

Inhibitors of bile acid transport in development at Aventis for lipid disorders

New class of peptides useful as selective alpha1-adrenoceptor antagonists

Vertex and Novartis create new model for drug discovery

Genzyme Transgenics and Genzyme General receive orphan drug designation

Immtech corners fungal disease with DB-368 compound

Protherics' high blood pressure vaccine moves to next phase

Alliance and Baxter join resources for developing Oxygent

Specific beta1-adrenoceptor blockade with antisense oligonucleotides for hypertension

Pfizer/Warner-Lambert merger expected to close in early June

Anti-ICAM-1 antisense oligonucleotide has beneficial effects in hepatic ischemia/reperfusion injury

JAK3 tyrosine kinase inhibitor PNU-156804 protects against rat heart allograft rejection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...